Español
EUR €
MT2: pigmentation research, the Irish context and evidence limits
Sources checked: 22 October 2026.
MT2 is the PP catalogue name for the research material identified in scientific publications as Melanotan-II. It is a cyclic analogue of alpha-melanocyte-stimulating hormone. Searches about pigmentation often mix an early human experiment, commercial product claims and public-health advice. Those sources answer different questions.
What the original human pilot measured
Dorr and colleagues, 1996 reported a single-blind, placebo-controlled phase-I pilot in three male volunteers. Two showed increased pigmentation, assessed by reflectance measurements and visual observation. Nausea, yawning and spontaneous erections were reported; one participant experienced somnolence and fatigue. This was an early experiment with a specified research preparation, not a test of PP material.
Why three participants cannot establish safety
A small pilot can identify responses worth investigating. It cannot reliably estimate rare harms, long-term outcomes or differences between wider groups. Two observations out of three are particularly sensitive to one person’s result. Presenting that fraction as a general success rate would imply a precision the study does not support. Pigmentation was the observed outcome; prevention of skin damage was not demonstrated.
The Irish public-health context
The HSE information on melanotan distinguishes melanotan from afamelanotide used in medical care. It states that melanotan is not a licensed medicine or approved cosmetic and warns about uncertain product quality and adverse effects. The HSE also explains that a tan does not protect against sunburn or sun damage. A change in colour is therefore not evidence of UV protection.
Four questions to keep separate
| Question | Relevant evidence |
|---|---|
| Did pigmentation change? | Measurements in the stated trial population. |
| Is a material correctly identified? | An analytical method and identified sample. |
| Is it safe for a particular use? | Evidence appropriate to that use and population. |
| Does a vial contain the declared mass? | A quantitative test of the specific submitted sample. |
MT2 10 mg: what the specification means
The 10 mg format describes declared total material per vial. It does not describe concentration per millilitre, a human-use amount or equivalence to a clinical preparation. Identity, purity and quantity are separate analytical questions. A purity percentage alone does not show how much material is present, and none of these measurements alone establishes sterility.
Available documentation
No independent MT2 report is currently published in the PP register. We do not substitute a target purity for a measured result. When comparing a publication with a product, check the substance, preparation, participants, comparator, follow-up and endpoint. This guide explains selected sources rather than providing a systematic review. PP supplies material exclusively for laboratory research, not human or veterinary use.